AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
183.17
-1.27 (-0.69%)
At close: 4:00PM EDT

183.17 0.00 (0.00%)
After hours: 4:53PM EDT

Stock chart is not supported by your current browser
Previous Close184.44
Open184.71
Bid182.08 x 1000
Ask187.10 x 1200
Day's Range182.74 - 184.71
52 Week Range166.30 - 210.19
Volume2,124,601
Avg. Volume2,849,250
Market Cap111.722B
Beta (3Y Monthly)0.91
PE Ratio (TTM)14.61
EPS (TTM)12.54
Earnings DateJul 30, 2019
Forward Dividend & Yield5.80 (3.14%)
Ex-Dividend Date2019-05-16
1y Target Est205.10
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket

    SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen (AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientific programs. Amgen has been sponsoring MBC BioLabs since 2016 to assist high-potential and innovative early-stage life science and biotech companies in their efforts to accelerate the development of new therapies to improve human health.

  • The 10 Biggest Biotech Stocks
    Motley Fool2 days ago

    The 10 Biggest Biotech Stocks

    Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

  • Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
    Zacks3 days ago

    Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

    Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch5 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • Amgen (AMGN) Gains But Lags Market: What You Should Know
    Zacks7 days ago

    Amgen (AMGN) Gains But Lags Market: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $184.08, moving +0.72% from the previous trading session.

  • The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

  • PR Newswire8 days ago

    Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

    THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. Under the terms of the agreement, Amgen has provided initial funding for three sponsored research projects that will seek to apply IPD's de novo design technique to increase the versatility of traditional protein-based medicines. This will include optimizing Amgen's repertoire of BiTE® (bispecific T cell enager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules.

  • 3 Large-Cap Biotech Stocks to Buy for Massive Gains
    InvestorPlace8 days ago

    3 Large-Cap Biotech Stocks to Buy for Massive Gains

    Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AMGN had net inflows of $3.22 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. AMGN credit default swap spreads are decreasing, indicating some improvement in the market's perception of the company's credit worthiness. Additionally, they are within the middle of the range set over the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire11 days ago

    Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

    Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative ...

  • PR Newswire15 days ago

    Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. On 22 May 2019 at 08:00 CEST, Amgen Inc. ("Amgen") (AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer") for SEK 32.50 per share in cash (the "Offer Price").(1) Nuevolution's shares are listed on Nasdaq Stockholm, Small Cap.

  • PR Newswire20 days ago

    Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    THOUSAND OAKS, Calif. , June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday , June 12, 2019, in Rancho ...

  • Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019
    CNW Group22 days ago

    Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019

    MISSISSAUGA, ON , June 5, 2019 /CNW/ - Amgen (AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels.

  • Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
    CNW Group22 days ago

    Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019

    MISSISSAUGA, ON , June 5, 2019 /CNW/ - Amgen (AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago . Data presented included updated investigational AMG 420 results in patients with relapsed and/or refractory multiple myeloma (R/R MM), as well as initial results from the investigational AMG 212 (pasotuxizumab) first-in-human trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • GuruFocus.com23 days ago

    Amgen Drug Breaks New Ground

    Amgen Inc. (AMGN) has accomplished something cancer researchers have failed to do for decades. The company presented results of an early-stage trial for the drug AMG 510 at the American Society of Clinical Oncology meeting on June 3 in Chicago. Over the following two days, Amgen's shares climbed more than $4.

  • Reuters23 days ago

    FDA approves Lilly's migraine drug as first ever cluster headache treatment

    Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration said https://reut.rs/2QMtzVE. Emgality belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency. It competes with Ajovy from Teva Pharmaceutical Industries Ltd and Amgen Inc's Aimovig, all approved within months of each other last year, creating a fierce battle for market share.

  • Barrons.com23 days ago

    Amgen’s Good News on Lung Cancer Boosted Mirati Therapeutics. Here’s What Wall Street Is Saying.

    Progress by Amgen in developing a lung-cancer drug lifted the small biotech company Mirati Therapeutics on Monday. Now, Wall Street analysts are raising their price targets for Mirati.

  • Reuters23 days ago

    Sanofi loses German patent case against Amgen over cholesterol drug

    Germany's highest civil court on Tuesday rejected French drugmaker Sanofi's bid to fend off a legal challenge by U.S. rival Amgen against Sanofi's cholesterol drug Praluent. In the latest setback for Sanofi in the drawn-out patent dispute with Amgen, which is selling its rival drug Repatha, the German court ruled that Sanofi was not entitled to a special licence that would have protected its Praluent business. Officials at Sanofi did not have an immediate comment.

  • Benzinga23 days ago

    How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

    Mirati Therapeutics Inc (NASDAQ: MRTX )'s shares have been on a tear, advancing over 50 percent since Amgen, Inc. (NASDAQ: AMGN ) uploaded an  online abstract of its non-small cell lung cancer candidate May ...

  • Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity
    Zacks23 days ago

    Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

    At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

  • Company News For Jun 4, 2019
    Zacks23 days ago

    Company News For Jun 4, 2019

    Companies In The News Are: EE,CY,AMGN,MRK

  • 3 Cancer Stocks Given a Lift by Amgen
    Motley Fool23 days ago

    3 Cancer Stocks Given a Lift by Amgen

    Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.

  • Reuters24 days ago

    US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

    The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators. While the sell-off in the internet heavyweights was the biggest drag on the Nasdaq, the index has been falling steadily since its May 3 record closing high as investors worried about slowing global growth amid an escalating U.S.-China trade war. The S&P 500 had a volatile session and ended the day down 0.3 percent, but the Dow Jones Industrial Average ended the session virtually unchanged.

  • Associated Press24 days ago

    Amgen and PHV rise while Alphabet and Centene slip

    Stocks that moved substantially or traded heavily on Monday: Cypress Semiconductor Corp., up $4.25 to $22.07 German chipmaker Infineon is buying the company for more than $10 billion in cash. Centene Corp., ...